Stock options grant to Gyre Therapeutics (GYRE) CFO Ruoyu Chen

Rhea-AI Filing Summary

Gyre Therapeutics, Inc. disclosed that its Chief Financial Officer, Ruoyu Chen, received a grant of stock options on January 7, 2026. The award is an option to purchase 50,000 shares of Gyre’s common stock at an exercise price of $7.31 per share.

According to the terms, 25% of the option will vest on January 7, 2027, with the remaining portion vesting in equal monthly installments over the following three years, subject to Chen’s continued service with the company through each vesting date. After this grant, Chen holds 50,000 stock options directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Chen Ruoyu

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	50,000	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 50,000 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Chen Ruoyu

(Last) (First) (Middle)

C/O GYRE THERAPEUTICS, INC.

12770 HIGH BLUFF DRIVE, SUITE 150

(Street)

SAN DIEGO CA 92130

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
GYRE THERAPEUTICS, INC. [ GYRE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/07/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$7.31	01/07/2026		A		50,000		(1)	01/07/2036	Common Stock	50,000	$0	50,000	D

Explanation of Responses:

1. This option represents a right to purchase a total of 50,000 shares of the Issuer's common stock, 25% of which will vest on January 7, 2027, with the remaining vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer through each vesting date.

	/s/ Ruoyu Chen	01/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did GYRE report in this Form 4?

The company reported a grant of a stock option to Chief Financial Officer Ruoyu Chen, covering 50,000 shares of common stock.

How many stock options did the GYRE CFO receive?

Ruoyu Chen received a stock option for 50,000 shares of Gyre Therapeutics, Inc. common stock.

What is the exercise price of the GYRE CFO’s stock options?

The stock option has an exercise price of $7.31 per share for the underlying common stock.

What is the vesting schedule for the GYRE CFO’s 50,000 options?

The option vests 25% on January 7, 2027, with the remaining shares vesting in equal monthly installments over the next three years, subject to continued service.

How many derivative securities does the GYRE CFO hold after this grant?

Following this transaction, Ruoyu Chen beneficially owns 50,000 stock options, held directly.

Is the GYRE CFO’s ownership reported as direct or indirect?

The Form 4 reports the CFO’s ownership of these 50,000 stock options as direct.